Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:20:15 EST Thu 13 Nov 2025
Enter Symbol
or Name
USA
CA



AI Heart Tech Breakthrough - Ellis Martin Interviews Dustin Haines, CEO Echo IQ Limited (ECHQF)

2025-11-12 17:29 ET - News Release

Malibu, CA, United States, Nov 12, 2025 - (ABN Newswire) - On this episode of The Ellis Martin Report on the MoneyTalk Radio Network, Ellis Martin speaks with Dustin Haines, Chief Executive Officer of Echo IQ Limited (ASX:EIQ) (OTCMKTS:ECHQF).

Echo IQ is an Australian-based company pioneering artificial intelligence solutions for cardiovascular diagnostics. Through its FDA-cleared Echo Solv technology, the firm uses AI-driven analysis of echocardiograms to help physicians detect aortic stenosis and other heart conditions earlier and more accurately.

In this discussion, Haines explains how Echo IQ's algorithms create a three-dimensional "digital fingerprint" of the human heart, why physician trust in AI matters, and how conversations with leading U.S. institutions - including the Mayo Clinic - highlight the company's expanding reach in cardiovascular diagnostics.

To Listen to the Interview, please visit:
https://www.abnnewswire.net/lnk/N8O57EO5


About Echo IQ Limited:

Echo IQ Limited (ASX:EIQ) (OTCMKTS:ECHQF) use the AI-powered technology in EchoSolv to enhance the diagnosis of structural heart disease. Our mission is to help improve the lives of people by supporting earlier, more accurate detection of a number of life-threatening but often treatable conditions.

About The Ellis Martin Report:

The Ellis Martin Report (TEMR) and Money Talk Radio feature interviews with industry leaders in mining, biotech, energy, and technology. The program is globally syndicated through multiple financial platforms and streaming services.

Contact:
 
T: +61 (0) 2 9159 3719 
W: echoiq.ai
E: cosec@echoiq.ai


Source:
Echo IQ Limited The Ellis Martin Report

Copyright (C) 2025 ABN Newswire. All rights reserved.

© 2025 Canjex Publishing Ltd. All rights reserved.